PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

This study has been completed.

Sponsor:

Collaborator:

National Cancer Institute (NCI)

Information provided by:

Cancer and Leukemia Group B

ClinicalTrials.gov Identifier:

NCT00053885

First received: February 5, 2003

Last updated: March 17, 2011

Last verified: March 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2006
Primary Completion Date:	July 2005 (Final data collection date for primary outcome measure)

Publications:

Jahan TM, Gu L, Wang X, et al.: Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). [Abstract] J Clin Oncol 24 (Suppl 18): A-7081, 2006.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun;76(3):393-6. Epub 2011 Dec 22.

To Top